{"transactions":[{"id":2217391,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":75749,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"timeliness","element":"transactionTimeliness","label":"F5","text":"Pursuant to the terms of the Merger Agreement, the Issuer's outstanding Series A Warrants (the \"Series A Warrants\") were treated in accordance with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Vivo Capital IX, LLC (\"Vivo Capital IX LLC\") is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Vivo Capital IX LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Ventures VII, LLC (\"Vivo Ventures LLC\") is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Vivo Ventures LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":75749},"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2217390,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":1455384,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"timeliness","element":"transactionTimeliness","label":"F5","text":"Pursuant to the terms of the Merger Agreement, the Issuer's outstanding Series A Warrants (the \"Series A Warrants\") were treated in accordance with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Vivo Capital IX, LLC (\"Vivo Capital IX LLC\") is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Vivo Capital IX LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Opportunity, LLC (\"Vivo Opportunity LLC\") is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":1455384},"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2217389,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":324740,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"timeliness","element":"transactionTimeliness","label":"F5","text":"Pursuant to the terms of the Merger Agreement, the Issuer's outstanding Series A Warrants (the \"Series A Warrants\") were treated in accordance with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Vivo Capital IX, LLC (\"Vivo Capital IX LLC\") is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Vivo Capital IX LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital IX, LLC (\"Vivo Capital IX LLC\") is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Vivo Capital IX LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":324740},"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2217388,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":431947,"price":55,"value":23757085.0,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Capital IX, LLC (\"Vivo Capital IX LLC\") is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Vivo Capital IX LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2217387,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":2735853,"price":55,"value":150471915.0,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Opportunity, LLC (\"Vivo Opportunity LLC\") is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2217386,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T16:59:45.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":161712,"price":55,"value":8894160.0,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc (\"GSK\"), Orikum Acquisition Inc. (\"Merger Sub\") and the Issuer (the \"Merger Agreement\"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the \"Merger\"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Ventures VII, LLC (\"Vivo Ventures LLC\") is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Vivo Ventures LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-22-036724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022036724/ownership.xml","form_type":"4"}},{"id":2421164,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-31T21:30:36.000Z","date":"2022-01-31","kind":"purchase","acquired":true,"shares":800000,"price":27,"value":21600000.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2735853,"source":{"system":"sec-edgar","filing":"0001213900-22-004647","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004647/ownership.xml","form_type":"4"}},{"id":2422603,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (Right to Purchase )","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":324740,"price":13.2,"value":4286568.0,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Warrants will expire on the 75th day anniversary of the Issuer's announcement of the top-line data results from MOMENTUM. The Issuer announced such data on January 25, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang are managing members of Vivo Capital IX, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund IX, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":107164},"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422602,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (Right to Purchase )","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":1455384,"price":13.2,"value":19211068.8,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Warrants will expire on the 75th day anniversary of the Issuer's announcement of the top-line data results from MOMENTUM. The Issuer announced such data on January 25, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":480277},"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422601,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (Right to Purchase )","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":75749,"price":13.2,"value":999886.8,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Warrants will expire on the 75th day anniversary of the Issuer's announcement of the top-line data results from MOMENTUM. The Issuer announced such data on January 25, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Fund VII. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":24996},"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422600,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":107164,"price":13.2,"value":1414564.8,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang are managing members of Vivo Capital IX, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund IX, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":431947,"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422599,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":480277,"price":13.2,"value":6339656.4,"ownership":{"direct":false,"nature":"By: Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his or her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1935853,"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":2422598,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T20:12:59.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":24996,"price":13.2,"value":329947.2,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock was effected. The number of Series B warrants being exercised, the number of shares of Common Stock issued upon exercise of the Series B Warrants and the exercise price of the Series B Warrants as disclosed hereof all reflect the 1-for-40 reverse split against the original numbers as disclosed in the Reporting Persons' Form 3, filed with the Securities and Exchange Commission on December 2, 2019. Each Series B Warrant is exercisable for 0.33 share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Fund VII. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":161712,"source":{"system":"sec-edgar","filing":"0001213900-22-004318","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390022004318/ownership.xml","form_type":"4"}},{"id":3296793,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":false,"shares":4287,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"shares","element":"transactionShares","label":"F8","text":"Consists of 4,287 shares of Series A Preferred Stock held by Vivo Capital Fund IX, L.P., which are convertible into an aggregate of 324,783 shares of Common Stock, as adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu are managing members of Vivo Capital IX, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund IX, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":324783},"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3296792,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":false,"shares":19213,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"shares","element":"transactionShares","label":"F7","text":"Consists of 19,213 shares of Series A Preferred Stock held by Vivo Opportunity Fund, L.P., which are convertible into an aggregate of 1,455,576 shares of Common Stock, as adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1455576},"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3296791,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":false,"shares":1000,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"shares","element":"transactionShares","label":"F6","text":"Consists of 1,000 shares of Series A Preferred Stock held by Vivo Fund VII, which are convertible into an aggregate of 75,759 shares of Common Stock, as adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Fund VII. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":75759},"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3296790,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":true,"shares":324783,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Vivo Capital Fund IX, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P., the record holder of the securities. Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu are managing members of Vivo Capital IX, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund IX, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":324783,"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3296789,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":true,"shares":1455576,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang are managing members of Vivo Opportunity, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":1455576,"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3296788,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":130985,"kind":"organization","name":"Vivo Opportunity Fund, L.P.","position":2,"cik":"0001726403","reported_name":"Vivo Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110673,"kind":"organization","name":"Vivo Capital IX, LLC","position":3,"cik":"0001750698","reported_name":"Vivo Capital IX, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110674,"kind":"organization","name":"Vivo Capital Fund IX, L.P.","position":4,"cik":"0001750117","reported_name":"Vivo Capital Fund IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":5,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":6,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":7,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-31T20:00:19.000Z","date":"2020-01-29","kind":"exercise","acquired":true,"shares":75759,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. (\"Vivo Fund VII\"), the record holder of the securities. Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Fund VII. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":136715,"source":{"system":"sec-edgar","filing":"0001213900-20-002313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750698/000121390020002313/ownership.xml","form_type":"4"}},{"id":3828403,"issuer":{"id":159340,"kind":"organization","name":"AIRXPANDERS INC","symbol":"AXP.AX"},"owners":[{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":1,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":2,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":3,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-31T20:50:11.000Z","date":"2018-08-30","kind":"purchase","acquired":true,"shares":429631,"price":0.1672,"value":71834.3032,"ownership":{"direct":false,"nature":"By Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P., the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In addition, Albert Cha, Frank Kung, Edgar Engleman, Chen Yu and Shan Fu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":788873,"source":{"system":"sec-edgar","filing":"0001615774-18-009063","document":"s112489_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1387156/000161577418009063/s112489_form4.xml","form_type":"4"}},{"id":3828402,"issuer":{"id":159340,"kind":"organization","name":"AIRXPANDERS INC","symbol":"AXP.AX"},"owners":[{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":1,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":2,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":3,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-31T20:50:11.000Z","date":"2018-08-30","kind":"purchase","acquired":true,"shares":19712492,"price":0.1672,"value":3295928.6624,"ownership":{"direct":false,"nature":"By Vivo Ventures Fund VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Ventures VII, LLC is the general partner of each of Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P., the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In addition, Albert Cha, Frank Kung, Edgar Engleman, Chen Yu and Shan Fu are managing members of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":36195409,"source":{"system":"sec-edgar","filing":"0001615774-18-009063","document":"s112489_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1387156/000161577418009063/s112489_form4.xml","form_type":"4"}},{"id":4206971,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":1,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":2,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":3,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-09-19T00:52:46.000Z","date":"2017-09-14","kind":"sale","acquired":false,"shares":22610,"price":5.775,"value":130572.75,"ownership":{"direct":false,"nature":"By Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Ventures VII, LLC is the general partner of Vivo Ventures VII Affiliates Fund, L.P., the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, each of Frank Kung, Edgar Engleman, Albert Cha, Chen Yu and Shan Fu is a managing member of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Ventures VII Affiliates Fund, L.P. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":90330,"source":{"system":"sec-edgar","filing":"0001615774-17-005168","document":"s107541_f4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000161577417005168/s107541_f4.xml","form_type":"4"}},{"id":4206970,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":1,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":2,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":3,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-09-19T00:52:46.000Z","date":"2017-09-14","kind":"sale","acquired":false,"shares":1037390,"price":5.775,"value":5990927.25,"ownership":{"direct":false,"nature":"By Vivo Ventures Fund VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Ventures VII, LLC is the general partner of Vivo Ventures Fund VII, L.P., the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, each of Frank Kung, Edgar Engleman, Albert Cha, Chen Yu and Shan Fu is a managing member of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Ventures Fund VII, L.P. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":4144495,"source":{"system":"sec-edgar","filing":"0001615774-17-005168","document":"s107541_f4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000161577417005168/s107541_f4.xml","form_type":"4"}},{"id":4408525,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":1,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":2,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":3,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-03-02T20:44:59.000Z","date":"2017-03-02","kind":"sale","acquired":false,"shares":2666,"price":31.2,"value":83179.2,"ownership":{"direct":false,"nature":"By Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.86, inclusive. The reporting person undertakes to provide to Aclaris Therapeutics, Inc., any security holder of Aclaris Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Ventures VII, LLC is the general partner of Vivo Ventures VII Affiliates Fund, L.P., the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Each of Frank Kung, Edgar Engleman, Albert Cha, Chen Yu and Shan Fu is a managing member of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Ventures VII Affiliates Fund, L.P. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":60972,"source":{"system":"sec-edgar","filing":"0001615774-17-000876","document":"s105466_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1509160/000161577417000876/s105466_form4.xml","form_type":"4"}},{"id":4408524,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":1,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":2,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":3,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-03-02T20:44:59.000Z","date":"2017-03-02","kind":"sale","acquired":false,"shares":122334,"price":31.2,"value":3816820.8,"ownership":{"direct":false,"nature":"By Vivo Ventures Fund VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.86, inclusive. The reporting person undertakes to provide to Aclaris Therapeutics, Inc., any security holder of Aclaris Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Ventures VII, LLC is the general partner of Vivo Ventures Fund VII, L.P., the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Each of Frank Kung, Edgar Engleman, Albert Cha, Chen Yu and Shan Fu is a managing member of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Ventures Fund VII, L.P. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2797597,"source":{"system":"sec-edgar","filing":"0001615774-17-000876","document":"s105466_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1509160/000161577417000876/s105466_form4.xml","form_type":"4"}},{"id":4408523,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":1,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":2,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":3,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-03-02T20:44:59.000Z","date":"2017-03-01","kind":"sale","acquired":false,"shares":2133,"price":30.98,"value":66080.34,"ownership":{"direct":false,"nature":"By Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.20, inclusive. The reporting person undertakes to provide to Aclaris Therapeutics, Inc., any security holder of Aclaris Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Ventures VII, LLC is the general partner of Vivo Ventures VII Affiliates Fund, L.P., the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Each of Frank Kung, Edgar Engleman, Albert Cha, Chen Yu and Shan Fu is a managing member of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Ventures VII Affiliates Fund, L.P. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":63638,"source":{"system":"sec-edgar","filing":"0001615774-17-000876","document":"s105466_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1509160/000161577417000876/s105466_form4.xml","form_type":"4"}},{"id":4408522,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":1,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":2,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":3,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-03-02T20:44:59.000Z","date":"2017-03-01","kind":"sale","acquired":false,"shares":97867,"price":30.98,"value":3031919.66,"ownership":{"direct":false,"nature":"By Vivo Ventures Fund VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.20, inclusive. The reporting person undertakes to provide to Aclaris Therapeutics, Inc., any security holder of Aclaris Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Ventures VII, LLC is the general partner of Vivo Ventures Fund VII, L.P., the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Each of Frank Kung, Edgar Engleman, Albert Cha, Chen Yu and Shan Fu is a managing member of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Ventures Fund VII, L.P. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":2919931,"source":{"system":"sec-edgar","filing":"0001615774-17-000876","document":"s105466_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1509160/000161577417000876/s105466_form4.xml","form_type":"4"}},{"id":4408521,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":1,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":2,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":3,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-03-02T20:44:59.000Z","date":"2017-02-28","kind":"sale","acquired":false,"shares":4266,"price":30.5,"value":130113.0,"ownership":{"direct":false,"nature":"By Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Ventures VII, LLC is the general partner of Vivo Ventures VII Affiliates Fund, L.P., the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Each of Frank Kung, Edgar Engleman, Albert Cha, Chen Yu and Shan Fu is a managing member of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Ventures VII Affiliates Fund, L.P. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":65771,"source":{"system":"sec-edgar","filing":"0001615774-17-000876","document":"s105466_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1509160/000161577417000876/s105466_form4.xml","form_type":"4"}},{"id":4408520,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":1,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":2,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":3,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-03-02T20:44:59.000Z","date":"2017-02-28","kind":"sale","acquired":false,"shares":195734,"price":30.5,"value":5969887.0,"ownership":{"direct":false,"nature":"By Vivo Ventures Fund VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Ventures VII, LLC is the general partner of Vivo Ventures Fund VII, L.P., the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Each of Frank Kung, Edgar Engleman, Albert Cha, Chen Yu and Shan Fu is a managing member of Vivo Ventures VII, LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Ventures Fund VII, L.P. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":3017798,"source":{"system":"sec-edgar","filing":"0001615774-17-000876","document":"s105466_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509160/000161577417000876/s105466_form4.xml","form_type":"4"}},{"id":4548417,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":1,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":2,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":3,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-18T19:44:08.000Z","date":"2016-11-18","kind":"sale","acquired":false,"shares":9598,"price":22.72,"value":218066.56,"ownership":{"direct":false,"nature":"By Vivo Ventures VII Affiliates Fund, L.P."},"balance_after":70037,"source":{"system":"sec-edgar","filing":"0001615774-16-008485","document":"s104763_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1509160/000161577416008485/s104763_form4.xml","form_type":"4"}},{"id":4548416,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":1,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":2,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":3,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-18T19:44:08.000Z","date":"2016-11-18","kind":"sale","acquired":false,"shares":440402,"price":22.72,"value":10005933.44,"ownership":{"direct":false,"nature":"By Vivo Ventures Fund VII, L.P."},"balance_after":3213532,"source":{"system":"sec-edgar","filing":"0001615774-16-008485","document":"s104763_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1509160/000161577416008485/s104763_form4.xml","form_type":"4"}},{"id":4548415,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":1,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":2,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":3,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-18T19:44:08.000Z","date":"2016-11-16","kind":"sale","acquired":false,"shares":9765,"price":27.3,"value":266584.5,"ownership":{"direct":false,"nature":"By Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $24.90, inclusive. The reporting person undertakes to provide to Aclaris Therapeutics, Inc., any security holder of Aclaris Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"VV LLC is the general partner of Vivo Ventures VII Affiliates Fund, L.P. (\"VVAF\"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, each of Albert Cha, a director of the issuer, Frank Kung and Edgar Engleman is a managing member of VV LLC and may be deemed to share voting and dispositive power over the securities held by VVAF. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":79635,"source":{"system":"sec-edgar","filing":"0001615774-16-008485","document":"s104763_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1509160/000161577416008485/s104763_form4.xml","form_type":"4"}},{"id":4548414,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":1,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":2,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":3,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-11-18T19:44:08.000Z","date":"2016-11-16","kind":"sale","acquired":false,"shares":448063,"price":23.25,"value":10417464.75,"ownership":{"direct":false,"nature":"By Vivo Ventures Fund VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $24.90, inclusive. The reporting person undertakes to provide to Aclaris Therapeutics, Inc., any security holder of Aclaris Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Ventures VII, LLC (\"VV LLC\") is the general partner of Vivo Ventures Fund VII, L.P. (\"VVF\"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, each of Albert Cha, a director of the issuer, Frank Kung and Edgar Engleman is a managing member of VV LLC and may be deemed to share voting and dispositive power over the securities held by VVF. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":3653934,"source":{"system":"sec-edgar","filing":"0001615774-16-008485","document":"s104763_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509160/000161577416008485/s104763_form4.xml","form_type":"4"}},{"id":4605662,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":1,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"ten_percent_owner":true}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":2,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"ten_percent_owner":true}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":3,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2016-09-12T22:27:57.000Z","date":"2016-09-08","kind":"sale","acquired":false,"shares":2381,"price":4.2529,"value":10126.1549,"ownership":{"direct":false,"nature":"By Vivo Ventures VII Affiliates Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price shown is a weighted average sales price.  The shares were sold at prices ranging from $4.10 to $4.40 per share.  The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are owned directly by Vivo Ventures Affliates Fund VII, L.P.  Vivo Ventures VII, LLC is its general partner, and as such may be deemed to beneficially own these shares."}],"balance_after":112940,"source":{"system":"sec-edgar","filing":"0001225208-16-039231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000122520816039231/doc4.xml","form_type":"4"}},{"id":4605661,"issuer":{"id":6428,"kind":"organization","name":"CODEXIS, INC.","symbol":"CDXS"},"owners":[{"id":125711,"kind":"person","name":"VIVO VENTURES VII, LLC","position":1,"cik":"0001565020","reported_name":"VIVO VENTURES VII, LLC","relationship":{"ten_percent_owner":true}},{"id":125712,"kind":"person","name":"Vivo Ventures Fund VII, L.P.","position":2,"cik":"0001509160","reported_name":"Vivo Ventures Fund VII, L.P.","relationship":{"ten_percent_owner":true}},{"id":125713,"kind":"person","name":"Vivo Ventures VII Affiliates Fund, L.P.","position":3,"cik":"0001538309","reported_name":"Vivo Ventures VII Affiliates Fund, L.P.","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2016-09-12T22:27:57.000Z","date":"2016-09-08","kind":"sale","acquired":false,"shares":109219,"price":4.2529,"value":464497.4851,"ownership":{"direct":false,"nature":"By Vivo Ventures Fund VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price shown is a weighted average sales price.  The shares were sold at prices ranging from $4.10 to $4.40 per share.  The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Vivo Ventures Fund VII, L.P.  Vivo Ventures VII, LLC is its general partner, and as such may be deemed to beneficially own these shares."}],"balance_after":5181885,"source":{"system":"sec-edgar","filing":"0001225208-16-039231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1200375/000122520816039231/doc4.xml","form_type":"4"}}]}